Program
BV100
A development code. Also written as “BV100 (300 mg)”, “BV100 with 50 mg polymyxin B plus ceftazidime/avibactam” and “BV100 with 50 mg polymyxin B plus cefiderocol”.
Its studies are mostly in Bacterial Infections · Pneumonia, Bacterial · Meningitis, Bacterial · Pneumonia, Ventilator-Associated · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioVersys | 71 open or running | phase 2since Jan 4, 2023 | Oct 8, 2021 | Mar 2028phase 2 · NCT07431307 |
| BioVersys SAS | 42 open or running | phase 3since Jan 7, 2026 | Nov 10, 2020 | Dec 30, 2027phase 3 · NCT07326540 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2020First study: phase 1 study in Healthy SubjectsNew to BioVersys SASBioVersys SAS · NCT04636983 · 54 enrolled · Germany
- Oct 8, 2021BioVersys's first study: phase 1 study in Renal InsufficiencyNew to BioVersysBioVersys · NCT05086107 · 48 enrolled · Hungary
- Oct 9, 2021Phase 1 study in Healthy VolunteersBioVersys SAS · NCT05087069 · 16 enrolled · Germany
- Sep 7, 20222 phase 1 studiesBioVersys · NCT05537090, NCT05537142
- Jan 4, 2023Phase 2 study in Pneumonia, Ventilator-AssociatedBioVersys · NCT05685615 · 39 enrolled · Georgia, Greece, Hungary
- Jan 5, 20232 phase 1 studies in Bacterial InfectionsBioVersys · NCT05684718, NCT05684705
- Jan 7, 2026Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)Phase 3 reachedBioVersys SAS · NCT07326540 · 248 planned · Georgia
- Feb 17, 2026Phase 2 study in Meningitis, BacterialBioVersys · NCT07431307 · 120 planned
- Apr 28, 2026Phase 1 study in Healthy Adult ParticipantsBioVersys SAS · NCT07580586 · 16 planned · Austria
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)BioVersys SAS · NCT07326540
- Mar 2028Primary completion: phase 2 study in Meningitis, BacterialBioVersys · NCT07431307
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07580586Healthy Adult Participants · Austria | 1 | Recruiting | BioVersys SAS | Sep 30, 2026 | 16 |
| NCT07431307Meningitis, Bacterial | 2 | Not yet recruiting | BioVersys | Mar 2028 | 120 |
| NCT07326540Hospital Acquired Bacterial Pneumonia (HABP) · Georgia | 3 | Recruiting | BioVersys SAS | Dec 30, 2027 | 248 |
| NCT05684718Bacterial Infections · Hungary | 1 | Completed | BioVersys | Sep 30, 2023 | 16 |
| NCT05684705Bacterial Infections · Austria | 1 | Completed | BioVersys | Oct 30, 2024 | 35 |
| NCT05685615Pneumonia, Ventilator-Associated · Georgia, Greece, Hungary | 2 | Completed | BioVersys | Nov 1, 2024 | 39 |
| NCT05537142Healthy Participants · Hungary | 1 | Completed | BioVersys | Jul 30, 2024 | 33 |
| NCT05537090Healthy Volunteers · Hungary | 1 | Completed | BioVersys | Jul 31, 2023 | 16 |
| NCT05087069Healthy Volunteers · Germany | 1 | Completed | BioVersys SAS | Apr 8, 2022 | 16 |
| NCT05086107Renal Insufficiency · Hungary | 1 | Completed | BioVersys | May 30, 2022 | 48 |
| NCT04636983Healthy Subjects · Germany | 1 | Completed | BioVersys SAS | Dec 12, 2021 | 54 |
How it is read
Names in the registry
- “BV100”, 6 entries
- “BV100 (300 mg)”, 3 entries
- “BV100 with 50 mg polymyxin B plus ceftazidime/avibactam”, 1 entry
- “BV100 with 50 mg polymyxin B plus cefiderocol”, 1 entry
- “BV100 plus Polymyxin B”, 1 entry
Codes read as this program: BV100.
Conditions, from the studies’ own filings
- Bacterial Infections, 2 studies
- Pneumonia, Bacterial, 1 study
- Meningitis, Bacterial, 1 study
- Pneumonia, Ventilator-Associated, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.